Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Non-interventional, multi-center, international registry in patients with severe aortic stenosis (sAS) undergoing transcatheter aortic valve implantation (TAVI). The BENCHMARK Registry aims to implement standardized, reproducible and scalable quality improvement measures, which will help to reduce resource requirements, intensive care unit bed occupancy and overall length of hospitalization with uncompromised patient safety. The registry will consist of the following phases: - Retrospective phase (purpose: capture the status quo of each site prior to any Quality of Care improvement measures): The TAVI of patients being eligible for retrospective documentation must have been performed prior to the site's enrollment into the BENCHMARK prospective phase (follow-up: 30 days, 12 months). - Training: Each center will undergo an online BENCHMARK training, after 30 patients have been documented retrospectively. The contents of the training will be: Reflection on treatment pathways with the TAVI team, education on 8 defined Quality of Care improvement measures, followed by a center self-assessment (to self-assess the current alignment of hospital performance with the BENCHMARK Performance criteria). - Implementation phase: After having self-assessed the current alignment of hospital performance with the following BENCHMARK Performance Criteria, each center will start to introduce the tailored Quality of Care improvement measures to their hospital routine within a time frame of 2 months. - Prospective phase (purpose: to document the effects of defined quality of care improvement measure and to make sure patient safety is as least as good as in the retrospective phase. (8 months of recruitment, Follow-up: 30 days, 12 months)
Description: LoS in days
Measure: Evaluation of differences in length of stay (LoS) Time: 12 monthsDescription: According to Valve Academic Research Consortium-2 consensus (VARC-2) criteria
Measure: Complication rate (AEs), TAVI related safety outcomes Time: 30 daysDescription: According to Valve Academic Research Consortium-2 consensus (VARC-2) criteria
Measure: Complication rate (AEs), TAVI related safety outcomes Time: 12 monthsDescription: Assess the Quality of Life by using the Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ). Each question has a maximum score of 7 (response options from "not very much" to "very much"), giving the complete questionnaire a maximum total score of 112 with a higher score indicating improved Quality of Life.
Measure: Quality of Life assessment: Toronto Aortic Stenosis Quality of Life Questionnaire Time: 30 daysDescription: Assess the Quality of Life by using the Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ). Each question has a maximum score of 7 (response options from "not very much" to "very much"), giving the complete questionnaire a maximum total score of 112 with a higher score indicating improved Quality of Life.
Measure: Quality of Life assessment: Toronto Aortic Stenosis Quality of Life Questionnaire Time: 12 monthsDescription: To determine the proportion of early discharges in sAS patients undergoing TAVI
Measure: Resource utilization - Early discharge information Time: 12 monthsDescription: To determine the working hours per patient
Measure: Resource utilization - Working hours per patient Time: 12 monthsDescription: To determine the number of patients undergoing TAVI (per center)
Measure: Resource utilization - Number of TAVI patients in each center Time: 12 monthsDescription: Satisfaction score, scoring from 0 (extremely dissatisfied) to 40 (extremely satisfied)
Measure: Physician and patient satisfaction Time: 30 daysDescription: Satisfaction score, scoring from 0 (extremely dissatisfied) to 40 (extremely satisfied)
Measure: Physician and patient satisfaction Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports